DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial
- PMID:29705555
- DOI: 10.1016/j.parkreldis.2018.04.018
DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial
Abstract
Introduction: To evaluate the effect of DA-9701, a novel prokinetic drug, on gastric motility evaluated by magnetic resonance imaging in patients with Parkinson's disease (PD).
Methods: Forty PD patients were randomly allocated to receive either domperidone or DA-9701. Their gastric functions were evaluated using magnetic resonance imaging before and after 4-week treatment period. Information on levodopa daily dose, disease duration, and Unified PD Rating Scale scores was collected. In 18 patients (domperidone: 9, DA-9701: 9), plasma levodopa concentrations were determined. Primary outcome was assessed by a one-sided 95% confidence interval to show non-inferiority of DA-9701 vs. domperidone with a pre-determined non-inferiority margin of -10%.
Results: Thirty-eight participants (19 men and 19 women; mean age, 67.1 years) completed the study protocol (domperidone: DA-9701 = 19:19). Gastric emptying rate at 120 min (2-hr GER) was comparable between the 2 groups; it was not correlated with levodopa daily dose or disease duration or Unified PD Rating Scale scores (all p > 0.05). DA-9701 was not inferior to domperidone in changes of 2-hr GERs before and after the treatment (absolute difference, 4.0 %; one-sided 95% confidence interval, - 3.7 to infinity). However, a significant increase in 2-hr GER was observed only in DA-9701 group (54.5% and 61.8%, before and after treatment, respectively, p < 0.05). Plasma levodopa concentration showed an insignificant but increasing trend in DA-9701 group. There were neither adverse reactions nor deteriorations of parkinsonian symptoms observed in the study participants.
Conclusion: DA-9701 can be used for the patients with PD to enhance gastric motility without aggravating PD symptoms (ClinicalTrials.gov number:NCT03022201).
Keywords: Clinical trial; DA-9701; Domperidone; Gastric emptying; Parkinson's disease.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
- Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW.Soykan I, et al.Mov Disord. 1997 Nov;12(6):952-7. doi: 10.1002/mds.870120618.Mov Disord. 1997.PMID:9399220Clinical Trial.
- A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.Herring WJ, Assaid C, Budd K, Vargo R, Mazenko RS, Lines C, Ellenbogen A, Verhagen Metman L.Herring WJ, et al.Clin Neuropharmacol. 2017 Nov/Dec;40(6):255-260. doi: 10.1097/WNF.0000000000000241.Clin Neuropharmacol. 2017.PMID:29059133Clinical Trial.
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators.Ferreira JJ, et al.Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23.Lancet Neurol. 2016.PMID:26725544Clinical Trial.
- Does levodopa slow or hasten the rate of progression of Parkinson's disease?Fahn S; Parkinson Study Group.Fahn S, et al.J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5.J Neurol. 2005.PMID:16222436Review.
- [Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].Doi H, Sakakibara R, Kishi M, Tsuyuzaki Y, Tateno F, Hirai S.Doi H, et al.Rinsho Shinkeigaku. 2013;53(11):1382-5. doi: 10.5692/clinicalneurol.53.1382.Rinsho Shinkeigaku. 2013.PMID:24291998Review.Japanese.
Cited by
- DA-9701 (Motilitone): A Multi-Targeting Botanical Drug for the Treatment of Functional Dyspepsia.Jin M, Son M.Jin M, et al.Int J Mol Sci. 2018 Dec 13;19(12):4035. doi: 10.3390/ijms19124035.Int J Mol Sci. 2018.PMID:30551633Free PMC article.Review.
- Quantitative MRI evaluation of gastric motility in patients with Parkinson's disease: Correlation of dyspeptic symptoms with volumetry and motility indices.Cho J, Lee YJ, Kim YH, Shin CM, Kim JM, Chang W, Park JH.Cho J, et al.PLoS One. 2019 May 3;14(5):e0216396. doi: 10.1371/journal.pone.0216396. eCollection 2019.PLoS One. 2019.PMID:31050679Free PMC article.
- Herbal Therapies in Functional Gastrointestinal Disorders: A Narrative Review and Clinical Implication.Kim YS, Kim JW, Ha NY, Kim J, Ryu HS.Kim YS, et al.Front Psychiatry. 2020 Jul 10;11:601. doi: 10.3389/fpsyt.2020.00601. eCollection 2020.Front Psychiatry. 2020.PMID:32754057Free PMC article.Review.
- Gastrointestinal Dysfunction in Parkinson's Disease: Neuro-Gastroenterology Perspectives on a Multifaceted Problem.Tan AH, Chuah KH, Beh YY, Schee JP, Mahadeva S, Lim SY.Tan AH, et al.J Mov Disord. 2023 May;16(2):138-151. doi: 10.14802/jmd.22220. Epub 2023 May 24.J Mov Disord. 2023.PMID:37258277Free PMC article.
- Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study.Choi JH, Lee JY, Cho JW, Koh SB, Yang YS, Yoo D, Shin CM, Kim HT.Choi JH, et al.Mov Disord. 2020 Nov;35(11):1966-1976. doi: 10.1002/mds.28219. Epub 2020 Aug 6.Mov Disord. 2020.PMID:32761955Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical